Therapeutic Response

ER positive, HER2-negative, and PIK3CA amplification status confers therapeutic sensitivity to Capivasertib in combination with Fulvestrant in patients with Invasive Breast Carcinoma.

Statements

Source and description

Truqap (capivasertib) [product monograph]. HC. Health Canada approved capivasertib, in combination with fulvestrant, for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.